MiMedx Group, Inc. (MDXG) stock
Close on Nov 13, 2026Market cap $468.42MP/E –Yield –
MiMedx Group, Inc. saw revenue fall 22.8% to $303.73M over the twelve months to Sep 30, 2026. Operating income fell 146.7% to -$25.14M, moving the operating margin from 13.7% to -8.3%. At the latest close the market valued the company at $468.42M.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $468.42M
- P/E ratio
- –
- Price to sales
- 1.54
- Price to book
- 2.22
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $303.73M
- Net income
- -$19.19M
- EPS, diluted
- -$0.13
- Book value per share
- $1.45
- Diluted shares
- 146M
Trading
- Next earnings
- Feb 24, 2027 (estimated, after the close)
- Previous close
- $3.24
- Open
- $3.25
- Day's range
- $3.15 – $3.29
- Volume
- 1,127,509
- Average volume (20 days)
- 1,799,851
- Index membership
- Russell 2000 (since Jun 2021), Russell 3000 (since Aug 2021)
- Beta (5 years)
- 0.97
- 52-week range
- $3.02 – $7.63
- RSI (14 days)
- 25.9
- Volatility (1 year)
- 43.1%
- Relative volume
- 0.83×
- WACC
- 9.9%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | MDXG | S&P 500 | Difference | MDXG per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -31.6% | -3.0% | −28.5 pts | ||
| 3 months | -23.6% | -2.8% | −20.8 pts | ||
| Year to date | -52.6% | +11.5% | −64.1 pts | ||
| 1 year | -57.0% | +13.5% | −70.5 pts | ||
| 3 years | -47.9% | +77.7% | −125.6 pts | -19.5% | +21.1% |
| 5 years | -61.1% | +72.6% | −133.7 pts | -17.2% | +11.5% |
| 10 years | -65.5% | +308.2% | −373.7 pts | -10.1% | +15.1% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases MiMedx filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Results
- Results
- Results
- Results
About MiMedx
Surgical & Medical Instruments & Apparatus
MIMEDX develops and manufactures regenerative biomaterial products, primarily human placental allografts, animal-derived xenografts, and advanced wound dressings. The company operates across wound care, surgical specialties, and burn treatment sectors. Its product portfolio includes human placental membrane allografts, bovine collagen matrices, autologous platelet-rich plasma gels, and peptide matrices intended to assist in healing chronic wounds, surgical recovery, and internal tissue reinforcement. Customers include clinicians, hospitals, private physician practices, wound care clinics, ambulatory surgery centers, nursing homes, and federal healthcare facilities such as the Department of Veterans Affairs.
Company profile, executives and historyMiMedx stock: common questions
What is MiMedx's stock price?
MDXG closed at $3.21 on Nov 13, 2026, down 0.93% on the day. Over the past 52 weeks it traded between $3.02 and $7.63.
What is MiMedx's market cap?
MiMedx was worth $468.42M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is MDXG's P/E ratio?
MiMedx lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.13), so it has no meaningful P/E ratio.
How much revenue does MiMedx make?
MiMedx reported revenue of $303.73M for the twelve months to Sep 30, 2026, down 22.8% from a year earlier.
Does MiMedx pay a dividend?
No. MiMedx has not paid a cash dividend over the last twelve months.
When does MiMedx report earnings next?
MiMedx is expected to report Q4 FY2026 results on Feb 24, 2027, after the close. The date is estimated from its past reporting pattern until the company confirms it.
How has MDXG stock performed over the past year?
Including dividends, MDXG returned -57.0% over the past year, against +13.5% for the S&P 500.
How many MDXG shares are sold short?
9M shares were sold short at the latest FINRA report, 6.33% of the float, or 4.3 days of average trading volume.
Who are MiMedx's competitors?
Companies most similar to MiMedx by business, industry and size include AXGN, LMAT, RCEL, CERS, BVS.
See a number that looks wrong?